ArticleScientific reports2026
The evaluation of an HIV-PrEP drug on the vascular health outcomes in a diet-induced prediabetes condition rat model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The prevalence of both prediabetes and cardiovascular diseases (CVD) is a public health concern in high-risk individuals using HIV pre-exposure prophylaxis (HIV-PrEP) treatment. The combined effect of prediabetes and HIV-PrEP use on endothelial function remains underexplored. Hence, the aim of this study was to investigate the effects of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) on endothelial function, oxidative stress, inflammation and lipid markers. Prediabetes was induced using a high-fat high-carbohydrate diet over a 20-week period. Prediabetes diagnosis was confirmed using fasting blood glucose and an oral glucose tolerance test. FTC/TDF was orally administered to the rats for a further 12 weeks. Biochemical analysis was performed using colorimetric assays. The prediabetic animals had higher fasting blood glucose (FBG), vascular endothelial growth factor A (VEGF-A), endothelin-1(ET-1), nitric oxide (NO), NO/ET-1 ratio, hydrogen peroxide (H2O2), interleukin-6, tumour necrosis factor α (TNF-α), triglycerides(TG), low-density lipoprotein cholesterol (LDL-C), endothelial nitric oxide synthase (eNOS), total antioxidant capacity (TAOC) and lower high-density lipoprotein cholesterol (HDL-C) when compared to the non-prediabetic control. However, the FTC/TDF treatment increased VEGF-A, HDL-C, LDL-C and it reduced TGs, NO, NO/ET-1 ratio, H2O2, eNOS, TAOC, interleukin-6, TNF-α and had minimal effect on FBG and ET-1 levels in prediabetic animals .In the non-prediabetic state, FTC/TDF treatment increased VEGF-A, ET-1, NO, NO/ET-1 ratio, H2O2 and interleukin-6 while decreasing eNOS, TAOC, TNF-α and HDL-C and it had a minimal effect on FBG, LDL-C and TGs. FTC/TDF treatment could increase the risk of cardiovascular complications via oxidative stress and endothelial dysfunction. Further studies are needed to fully understand the molecular mechanisms underlying these observed effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.